ALNYAlnylam Pharmaceuticals, Inc.
Price
-49%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growth steady, the market undecided.
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $2.46B in H1 2026 (quarter ended Jun 30, 2026), up 314% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $370M (15% of revenue). For the full year FY2025, revenue was $3.71B (+65% year on year) and net income $314M. Its largest product in H1 2026 was Amvuttra at $809M, 67% of the disclosed total, well ahead of Rare at 12%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- May 27, 2026Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly …Director or officer change · Form 8-K
- Mar 4, 2026Effective March 2, 2026 (the “Grant Date”), the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) granted, following the recommendation of the People, Culture and Compensation Committee (the “Committee”), a special equity award (the “Special Award”) under the Company’s …Director or officer change · Form 8-K
- Dec 11, 2025On December 10, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% convertible senior notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggregate principal amount of …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
H1 2026 · $1.20BThe company’s own SEC segment disclosure.
- Amvuttra$809.1M67%
- Rare$141.9M12%
- Royalty$71.7M6%
- GIVLAARI$58.0M5%
- Collaborations$47.2M4%
- Development Services Obligation$40.2M3%
- Other (4)$35.9M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.